Evaluation of P-glycoprotein-mediated renal drug interactions in an MDR1-MDCK model

被引:19
作者
Karyekar, CS
Eddington, ND
Garimella, TS
Gubbins, PO
Dowling, TC
机构
[1] Univ Maryland, Sch Pharm, Pharmacokinet Biopharmaceut Lab, Baltimore, MD 21201 USA
[2] Univ Arkansas Med Sci, Coll Pharm, Little Rock, AR 72205 USA
来源
PHARMACOTHERAPY | 2003年 / 23卷 / 04期
关键词
D O I
10.1592/phco.23.4.436.32125
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Study Objective. To evaluate P-glycoprotein (P-gp)-mediated renal drug interactions in an in vitro model of tubular secretion. Design. In vitro experiment. Setting. University-affiliated pharmacokinetics laboratory. Cell Lines. Madin-Darby canine kidney (MDCK), multidrug-resistant-1 (MDR1)-MDCK, and human colon carcinoma (Caco-2) cells. Intervention. Transepithelial transport (basolateral-to-apical and apical-to-basolateral) of cimetidine was assessed in the absence and presence of various concentrations of the P-gp inhibitors itraconazole and PSC-833 in a renal P-gp cell culture model (MDR1-MDCK). Measurements and Main Results. Apparent permeability of cimetidine was characterized, and level of P-gp expression was determined by Western blot analysis, in MDCK (wild type), MDR1-MDCK, and Caco-2 cells (for relative comparison). in the presence of PSC-833, cimetidine's apparent permeability value for basolateral-to-apical transport decreased from 2.96 to 1.15 x 10(-6) cm/second, coupled with a decrease in efflux ratio from 2.36 to 1.80. The effect of itraconazole was concentration dependent, with cimetidine's apparent permeability value for basolateral-to-apical transport decreasing from 3.96 to 1.92 x 10(-6) cm/second (p<0.05), resulting in a 50% decrease in efflux ratio. Expression of P-gp was negligible in MDCK (wildtype) cells, but high-level expression was confirmed in both MDR1-MDCK and Caco-2 cells. Conclusion. P-glycoprotein plays a significant role in the renal tubular secretion of organic cations such as cimetidine, and the high level of P-gp expression in MDR1-MDCK cells makes this a well-suited model for evaluating mechanisms of renal drug interactions.
引用
收藏
页码:436 / 442
页数:7
相关论文
共 38 条
[1]   PHASE-I TRIAL OF DOXORUBICIN WITH CYCLOSPORINE AS A MODULATOR OF MULTIDRUG-RESISTANCE [J].
BARTLETT, NL ;
LUM, BL ;
FISHER, GA ;
BROPHY, NA ;
EHSAN, MN ;
HALSEY, J ;
SIKIC, BI .
JOURNAL OF CLINICAL ONCOLOGY, 1994, 12 (04) :835-842
[2]  
BERARDI RR, 1988, CLIN PHARMACY, V7, P271
[3]   Regulation of renal tubular secretion of organic compounds [J].
Berkhin, EB ;
Humphreys, MH .
KIDNEY INTERNATIONAL, 2001, 59 (01) :17-30
[4]   Phase I study of etoposide with SDZ PSC 833 as a modulator of multidrug resistance in patients with cancer [J].
Boote, DJ ;
Dennis, IF ;
Twentyman, PR ;
Osborne, RJ ;
Laburte, C ;
Hensel, S ;
Smyth, JF ;
Brampton, MH ;
Bleehen, NM .
JOURNAL OF CLINICAL ONCOLOGY, 1996, 14 (02) :610-618
[5]  
Cvetkovic M, 1999, DRUG METAB DISPOS, V27, P866
[6]   Characterization of tubular functional capacity in humans using para-aminohippurate and famotidine [J].
Dowling, TC ;
Frye, RF ;
Fraley, DS ;
Matzke, GR .
KIDNEY INTERNATIONAL, 2001, 59 (01) :295-303
[7]   Determination of famotidine in human plasma and urine by high-performance liquid chromatography [J].
Dowling, TC ;
Frye, RF .
JOURNAL OF CHROMATOGRAPHY B, 1999, 732 (01) :239-243
[8]  
DUTT A, 1994, J PHARMACOL EXP THER, V269, P1254
[9]  
Ernest S, 1998, KIDNEY INT, pS11
[10]   Epithelial transport of anthelmintic ivermectin in a novel model of isolated proximal kidney tubules [J].
Fricker, G ;
Gutmann, H ;
Droulle, A ;
Drewe, J ;
Miller, DS .
PHARMACEUTICAL RESEARCH, 1999, 16 (10) :1570-1575